Regulation (EC) No. 816/2006 of the European Parliament and of the Council of 17 May 2006 allows the compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems. The Regulation aims to implement a Decision of the World Trade Organisation (WTO) to give countries in need greater access to more affordable medicines (read more ).
|17.05.2006||Adoption of the Regulation|
|29.10.2006||Commission proposal to allow export of generic medicines to poor countries|
Notifications by importing countries
To be "eligible" to import medicines under the Regulation, a country needs to make a notification that it intends to use the system as an importer. Least-developed countries (LDCs) are automatically eligible and do not need to make this notification.
In order to make use of the system each eligible importing country must notify the products, quantities and certain other information it needs to import.
WTO Members make these notifications to the WTO, where they are published on a dedicated webpage
Non-WTO members make the notifications to the Commission and will be published below.
Notifications by exporting Member States
Any EU Member State which grants a compulsory licence under the Regulation must notifiy the WTO through the Commission. These notifications will be published below.
WTO Members other than EU Member States make these notifications to the WTO, where they are published on a dedicated webpage.